The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders

Journal of Clinical Investigation

Volumn 119, Issue 4, 2009, Pages 747-754

  Levitt, Pat ^a,b   Campbell, Daniel B ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; ONCOPROTEIN;

ALLELE; AUTISM; GENE INTERACTION; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HEREDITY; HERITABILITY; HUMAN; MUTATION; NERVE CELL DIFFERENTIATION; NEUROBIOLOGY; PREVALENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CHILD; FEMALE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALLELES; AUTISTIC DISORDER; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MODELS, GENETIC; MODELS, NEUROLOGICAL; MUTATION; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 65249140471     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37934     Document Type: Review

References (113)

1. Newschaffer, C.J., et al. 2007. The epidemiology of autism spectrum disorders. Annu. Rev. Public Health. 28:235-258.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association. Washington, DC, USA. 886 pp.
3. Knudsen, E.I. 2004. Sensitive periods in the development of the brain and behavior. J. Cogn. Neurosci. 16:1412-1425.
4. Thatcher, R. 1994. Psychopathology of early frontal lobe damage: dependence on cycles of development. Dev. Psychopathol. 6:565-596.
5. Hammock, E.A.D., and Levitt, P. 2006. The discipline of neurobehavioral development: the emerging interface of processes that build circuits and skills. Hum. Dev. 49:294-309.
6. Dawson, G., et al. 2002. Defining the broader phenotype of autism: genetic, brain, and behavioral perspectives. Dev. Psychopathol. 14:581-611.
7. Beauchaine, T.P., Strassberg, Z., Kees, M.R., and Drabick, D.A. 2002. Cognitive response repertoires to child noncompliance by mothers of aggressive boys. J. Abnorm. Child Psychol. 30:89-101.
8. Piven, J. 2001. The broad autism phenotype: a complementary strategy for molecular genetic studies of autism. Am. J. Med. Genet. 105:34-35.
9. Devlin, B., et al. 2005. Autism and the serotonin transporter: the long and short of it. Mol. Psychiatry. 10:1110-1116.
10. Rutter, M. 1996. Autism research: prospects and priorities. J. Autism Dev. Disord. 26:257-275.
11. Volkmar, F.R., Lord, C., Bailey, A., Schultz, R.T., and Klin, A. 2004. Autism and pervasive developmental disorders. J. Child Psychol. Psychiatry. 45:135-170.
12. Bailey, A., et al. 1995. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol. Med. 25:63-77.
13. Steffenburg, S., et al. 1989. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J. Child Psychol. Psychiatry. 30:405-416.
14. Geschwind, D.H., and Levitt, P. 2007. Autism spectrum disorders: developmental disconnection syndromes. Curr. Opin. Neurobiol. 17:103-111.
15. Veenstra-Vanderweele, J., Christian, S.L., and Cook, E.H., Jr. 2004. Autism as a paradigmatic complex genetic disorder. Annu. Rev. Genomics Hum. Genet. 5:379-405.
16. Abrahams, B.S., and Geschwind, D.H. 2008. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 9:341-355.
17. O'Roak, B.J., and State, M.W. 2008. Autism genetics: strategies, challenges, and opportunities. Autism Res. 1:4-17. doi:10.1002/aur.3.
18. Craddock, N., O'Donovan, M.C., and Owen, M.J. 2008. Genome-wide association studies in psychiatry: lessons from early studies of non-psychiatric and psychiatric phenotypes. Mol. Psychiatry. 13:649-653.
19. Cook, E.H., Jr., and Scherer, S.W. 2008. Copy-number variations associated with neuropsychiatric conditions. Nature. 455:919-923.
20. Sebat, J., et al. 2004. Large-scale copy number polymorphism in the human genome. Science. 305:525-528.
21. Rehen, S.K., et al. 2005. Constitutional aneuploidy in the normal human brain. J. Neurosci. 25:2176-2180.
22. Kingsbury, M.A., Yung, Y.C., Peterson, S.E., Westra, J.W., and Chun, J. 2006. Aneuploidy in the normal and diseased brain. Cell. Mol. Life Sci. 63:2626-2641.
23. Kingsbury, M.A., et al. 2005. Aneuploid neurons are functionally active and integrated into brain circuitry. Proc. Natl. Acad. Sci. U. S. A. 102:6143-6147.
24. Sebat, J., et al. 2007. Strong association of de novo copy number mutations with autism. Science. 316:445-449.
25. Marshall, C.R., et al. 2008. Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 82:477-488.
26. Campbell, D.B., et al. 2006. A genetic variant that disrupts MET transcription is associated with autism. Proc. Natl. Acad. Sci. U. S. A. 103:16834-16839.
27. Campbell, D.B., Li, C., Sutcliffe, J.S., Persico, A.M., and Levitt, P. 2008. Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res. 1:159-168. doi:10.1002/aur.27.
28. Losh, M., Sullivan, P.F., Trembath, D., and Piven, J. 2008. Current developments in the genetics of autism: from phenome to genome. J. Neuropathol. Exp. Neurol. 67:829-837.
29. Liu, X.Q., Paterson, A.D., and Szatmari, P. 2008. Genome-wide linkage analyses of quantitative and categorical autism subphenotypes. Biol. Psychiatry. 64:561-570.
30. Daiger, S.P., Bowne, S.J., and Sullivan, L.S. 2007. Perspective on genes and mutations causing retinitis pigmentosa. Arch. Ophthalmol. 125:151-158.
31. Porter, F.D. 2008. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 16:535-541.
32. Todd, J.A., et al. 2007. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39:857-864.
33. Zeggini, E., et al. 2007. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 316:1336-1341.
34. Samani, N.J., et al. 2007. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 357:443-453.
35. Bakkaloglu, B., et al. 2008. Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am. J. Hum. Genet. 82:165-173.
36. Kates, W.R., et al. 2007. Comparing phenotypes in patients with idiopathic autism to patients with velocardiofacial syndrome (22q11 DS) with and without autism. Am. J. Med. Genet. A. 143A:2642-2650.
37. Gothelf, D., et al. 2008. Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). Ann. Neurol. 63:40-51.
38. Nishimura, Y., et al. 2007. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum. Mol. Genet. 16:1682-1698.
39. Persico, A., and Bourgeron, T. 2006. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 29:349-358.
40. Walsh, C.A., Morrow, E.M., and Rubenstein, J.L.R. 2008. Autism and brain development. Cell. 135:396-400.
41. Zoghbi, H.Y. 2003. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 302:826-830.
42. Urdinguio, R.G., et al. 2008. Mecp2-null mice provide new neuronal targets for Rett syndrome. PLoS ONE. 3:e3669.
43. Kwon, C.H., Zhu, X., Zhang, J., and Baker, S.J. 2003. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:12923-12928.
44. Meikle, L., et al. 2008. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28:5422-5432.
45. Ehninger, D., et al. 2008. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 14:843-848.
46. Costa, R.M., et al. 2002. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 415:526-530.
47. Li, W., et al. 2005. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 15:1961-1967.
48. Network, T.C.G.A.R. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061-1068.
49. Ding, L., et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455:1069-1075.
50. Chalhoub, N., and Baker, S.J. 2008. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. Online publication ahead of print. doi:10.1146/ annurev.pathol.4.110807.092311.
51. Serajee, F.J., Nabi, R., Zhong, H., and Mahbubul Huq, A.H. 2003. Association of INPP1, PIK3CG, and TSC2 gene variants with autistic disorder: implications for phosphatidylinositol signalling in autism. J. Med. Genet. 40:e119.
52. Campbell, D.B., et al. 2007. Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann. Neurol. 62:243-250.
53. Harrison, P.J., and Law, A.J. 2006. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry. 60:132-140.
54. Kanakry, C.G., Li, Z., Nakai, Y., Sei, Y., and Weinberger, D.R. 2007. Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/ Akt-dependent pathway: potential implications for schizophrenia and cancer. PLoS ONE. 2:e1369.
55. Grinshpoon, A., et al. 2005. Cancer in schizophrenia: is the risk higher or lower? Schizophr. Res. 73:333-341.
56. Hippisley-Cox, J., Vinogradova, Y., Coupland, C., and Parker, C. 2007. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested casecontrol study. Arch. Gen. Psychiatry. 64:1368-1376.
57. Lichtermann, D., Ekelund, J., Pukkala, E., Tanskanen, A., and Lonnqvist, J. 2001. Incidence of cancer among persons with schizophrenia and their relatives. Arch. Gen. Psychiatry. 58:573-578.
58. Levav, I., et al. 2007. Cancer risk among parents and siblings of patients with schizophrenia. Br. J. Psychiatry. 190:156-161.
59. Catts, V.S., Catts, S.V., O'Toole, B.I., and Frost, A.D. 2008. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr. Scand. 117:323-336.
60. Norton, N., et al. 2006. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B:96-101.
61. Fox, I.J., and Kornblum, H.I. 2005. Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions. J. Neurosci. Res. 79:584-597.
62. Judson, M.C., Bergman, M.Y., Campbell, D.B., Eagleson, K.L., and Levitt, P. 2009. Dynamic gene and protein expression patterns of the autism-associated c-Met receptor tyrosine kinase in the developing mouse forebrain. J. Comp. Neurol. 513:511-531.
63. Hossain, M.A., Russell, J.C., Gomez, R., and Laterra, J. 2002. Neuroprotection by scatter factor/ hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/ akt-dependent and MAPK/CREB-independent. J. Neurochem. 81:365-378.
64. Liu, Y., et al. 2007. Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development. J. Pathol. 212:12-19.
65. Roggia, C., Ukena, C., Bohm, M., and Kilter, H. 2007. Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp. Cell Res. 313:921-930.
66. Cacci, E., et al. 2003. Hepatocyte growth factor stimulates cell motility in cultures of the striatal progenitor cells ST14A. J. Neurosci. Res. 74:760-768.
67. He, F., et al. 2008. HGF protects cultured cortical neurons against hypoxia/reoxygenation induced cell injury via ERK1/2 and PI-3K/Akt pathways. Colloids Surf. B Biointerfaces. 61:290-297.
68. [No authors listed]. 1998. A full genome screen for autism with evidence for linkage to a region on chromosome 7q. International Molecular Genetic Study of Autism Consortium. Hum. Mol. Genet. 7:571-578.
69. Philippe, A., et al. 1999. Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum. Mol. Genet. 8:805-812.
70. International Molecular Genetic Study of Autism Consortium. 2001. A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. Am. J. Hum. Genet. 69:570-581.
71. Lamb, J.A., et al. 2005. Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects. J. Med. Genet. 42:132-137.
72. Schellenberg, G.D., et al. 2006. Evidence for multiple loci from a genome scan of autism kindreds. Mol. Psychiatry. 11:1049-1060.
73. Powell, E.M., Mars, W.M., and Levitt, P. 2001. Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron. 30:79-89.
74. Levitt, P., Eagleson, K.L., and Powell, E.M. 2004. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci. 27:400-406.
75. Rubenstein, J.L., and Merzenich, M.M. 2003. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2:255-267.
76. Powell, E.M., et al. 2003. Genetic disruption of cortical interneuron development causes regionand GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J. Neurosci. 23:622-631.
77. Levitt, P. 2005. Disruption of interneuron development. Epilepsia. 46(Suppl. 7):22-28.
78. Eagleson, K.L., Bonnin, A., and Levitt, P. 2005. Regionand age-specific deficits in gamma-aminobutyric acidergic neuron development in the telencephalon of the uPAR(-/-) mouse. J. Comp. Neurol. 489:449-466.
79. Beilmann, M., et al. 1997. Neoexpression of the c-met/ hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood. 90:4450-4458.
80. Ieraci, A., Forni, P.E., and Ponzetto, C. 2002. Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc. Natl. Acad. Sci. U. S. A. 99:15200-15205.
81. Arthur, L.G., Schwartz, M.Z., Kuenzler, K.A., and Birbe, R. 2004. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. J. Pediatr. Surg. 39:139-143.
82. Okunishi, K., et al. 2005. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J. Immunol. 175:4745-4753.
83. Ido, A., Numata, M., Kodama, M., and Tsubouchi, H. 2005. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J. Gastroenterol. 40:925-931.
84. McCall-Culbreath, K.D., Li, Z., and Zutter, M.M. 2008. Crosstalk between the alpha2beta1 integrin and c-met/HGF-R regulates innate immunity. Blood. 111:3562-3570.
85. Jyonouchi, H., Geng, L., Ruby, A., and Zimmerman-Bier, B. 2005. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 51:77-85.
86. Valicenti-McDermott, M., et al. 2006. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J. Dev. Behav. Pediatr. 27:S128-S136.
87. Hansen, R.L., et al. 2008. Regression in autism: prevalence and associated factors in the CHARGE Study. Ambul. Pediatr. 8:25-31.
88. Xue, M., Brimacombe, M., Chaaban, J., Zimmerman-Bier, B., and Wagner, G.C. 2008. Autism spectrum disorders: concurrent clinical disorders. J. Child Neurol. 23:6-13.
89. Garbett, K., et al. 2008. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 30:303-311.
90. Enstrom, A.M., et al. 2009. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav. Immun. 23:124-133.
91. Sousa, I., et al. 2008. MET and autism susceptibility: family and case-control studies. Eur. J. Hum. Genet. Online publication ahead of print. doi: 10.1038/ ejhg.2008.215.
92. Ma, P.C., et al. 2003. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63:6272-6281.
93. Li, Z., Dong, T., Proschel, C., and Noble, M. 2007. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol. 5:e35.
94. Hood, D.B., Nayyar, T., Ramesh, A., Greenwood, M., and Inyang, F. 2000. Modulation in the developmental expression profile of Sp1 subsequent to transplacental exposure of fetal rats to desorbed benzo[a]pyrene following maternal inhalation. Inhal. Toxicol. 12:511-535.
95. Nayyar, T., Zawia, N.H., and Hood, D.B. 2002. Transplacental effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the temporal modulation of Sp1 DNA binding in the developing cerebral cortex and cerebellum. Exp. Toxicol. Pathol. 53:461-468.
96. Peters, S.U., Beaudet, A.L., Madduri, N., and Bacino, C.A. 2004. Autism in Angelman syndrome: implications for autism research. Clin. Genet. 66:530-536.
97. Veltman, M.W., Craig, E.E., and Bolton, P.F. 2005. Autism spectrum disorders in Prader-Willi and Angelman syndromes: a systematic review. Psychiatr. Genet. 15:243-254.
98. Bonati, M.T., et al. 2007. Evaluation of autism traits in Angelman syndrome: a resource to unfold autism genes. Neurogenetics. 8:169-178.
99. Lowenthal, R., Paula, C.S., Schwartzman, J.S., Brunoni, D., and Mercadante, M.T. 2007. Prevalence of pervasive developmental disorder in Down's syndrome. J. Autism Dev. Disord. 37:1394-1395.
100. Kent, L., Evans, J., Paul, M., and Sharp, M. 1999. Comorbidity of autistic spectrum disorders in children with Down syndrome. Dev. Med. Child Neurol. 41:153-158.
101. Garcia-Nonell, C., et al. 2008. Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. Am. J. Med. Genet. A. 146A:1911-1916.
102. Clifford, S., et al. 2007. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J. Autism Dev. Disord. 37:738-747.
103. Williams, P.G., and Hersh, J.H. 1998. Brief report: the association of neurofibromatosis type 1 and autism. J. Autism Dev. Disord. 28:567-571.
104. Butler, M.G., et al. 2005. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 42:318-321.
105. Potocki, L., et al. 2007. Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am. J. Hum. Genet. 80:633-649.
106. Chahrour, M., and Zoghbi, H.Y. 2007. The story of Rett syndrome: from clinic to neurobiology. Neuron. 56:422-437.
107. Ben Zeev Ghidoni, B. 2007. Rett syndrome. Child Adolesc. Psychiatr. Clin. N. Am. 16:723-743.
108. Tierney, E., et al. 2001. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. Am J. Med. Genet. 98:191-200.
109. Sikora, D.M., Pettit-Kekel, K., Penfield, J., Merkens, L.S., and Steiner, R.D. 2006. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J. Med. Genet. A. 140:1511-1518.
110. Splawski, I., et al. 2004. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 119:19-31.
111. Smalley, S.L. 1998. Autism and tuberous sclerosis. J. Autism Dev. Disord. 28:407-414.
112. Jeste, S.S., Sahin, M., Bolton, P., Ploubidis, G.B., and Humphrey, A. 2008. Characterization of autism in young children with tuberous sclerosis complex. J. Child Neurol. 23:520-525.
113. Philippe, A., et al. 2008. Neurobehavioral profile and brain imaging study of the 22q13.3 deletion syndrome in childhood. Pediatrics. 122:e376-e382.